Lucatumumab

Lucatumumab (CHIR 12.12 or HCD122)^[1] is a human monoclonal antibody against CD40^[2] development of which was discontinued by Novartis in 2013 after it was investigated for the treatment of various types of cancer like multiple myeloma and follicular lymphoma.^[3]

Lucatumumab

Monoclonal antibody
Type	Whole antibody
Source	Human
Target	CD40
Clinical data
ATC code	none
Identifiers
CAS Number	903512-50-5 N
ChemSpider	none
UNII	P0EP9VFC4R
KEGG	D08942 Y
Chemical and physical data
Molar mass	146 kg/mol
NY (what is this?)  (verify)

It is an antagonist to CD40 that was created by scientists at Chiron using Abgenix' XenoMouse transgenic mouse to generate fully human antibodies.^[4][5] It was made part of the collaboration between Chiron and Xoma that the companies commenced in 2004.^[6][7][8] Novartis took over the project when it acquired Chiron in 2005.^[9][10]

In in vitro studies, it inhibited cell proliferation induced by CD40 ligands and induced cell lysis.^[11]

Over three Phase 1 trials in multiple myeloma and chronic lymphocytic leukemia, the companies made an effort to determine the optimal dose, and obtained unclear results.^[1] The Phase I part of a planned Phase I/II trial in multiple myeloma was started in 2005, and in 2012 was updated to Phase II and closed; as of 2014 the results had not been published.^[1]